Latest News

Assessment of ZEN-3694 plus abemaciclib or cisplatin/etoposide in NUT carcinoma is ongoing across 2 active clinical trials.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

Melphalan, BCNU, B12, and ascorbic acid plus ASCT show promise for patients with metastatic PDAC, according to results from the SHARON trial.

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.

The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Explore how oncogenes and signaling pathways converge and diverge in cancer, shaping diagnostic and therapeutic strategies for personalized interventions.

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

Adam Friedman, MD, FAAD, discusses systemic barriers to timely dermatologic consultation for patients with cancer.

Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.

Results from the phase 1/2 AUGMENT-101 trial support the FDA’s decision for approving revumenib in this NPM1-mutated, relapsed/refractory AML population.

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.

A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.

The evaluation of MT-125’s safety and preliminary activity in glioblastoma is underway in a phase 1/2 trial.

Belantamab mafodotin has been approved for multiple myeloma despite the FDA’s ODAC committee voting against the treatment due to ocular toxicities.

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

Adam Friedman, MD, FAAD, discusses essential communication strategies for oncologists to address patient fears about dermatologic adverse effects.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.